Business Overview
About the Company
The Company provides comprehensive weight loss services to clients who are unable to lose weight due to life changing health conditions and have tried to lose weight through other methods and have failed. Over its decade-plus history, the Company has developed an outstanding reputation for its expertise and ability to deliver an unsurpassed level of client care while offering the latest all natural weight loss techniques including body contouring. The Company’s programs include proprietary products and nutraceuticals to reset the client’s metabolism. These products are all natural and a safe way to facilitate weight loss. The Company has two brick and mortar locations as well as a virtual location that provides nationwide sales.
INVESTMENT APPEAL
• Superior Reputation and Weight Loss Program — The Company enjoys excellent name recognition in its market and a long-standing (10+ years) reputation for quality products and superior customer care. The Company’s clients are overseen by doctors and incorporate the client’s lifestyle and nutritional programs that include proprietary nutraceuticals to assist in the weight loss process.
• Management Open to Stay for transition — Current ownership is flexible and willing to stay to secure a smooth transition to new owners.
• Outstanding Growth Opportunities — Management has successfully opened two additional locations in other states utilizing a low-cost approach to establish its brand and reputation. Investments in marketing, primarily via social media and offline efforts such as radio and TV, is being utilized to compound exposure in new markets. By leveraging its reputation and easy-to-replicate business model, the Company is poised to continue opening new locations in strategic markets.
• Advantageous Industry Outlook — According to a study led by Harvard T.H. Chan School of Public Health, about half of the adult U.S. population will have obesity and about a quarter will have severe obesity by 2030.
• Strong Revenue and Profit Trends — Sales have grown from $2,868,000 in 2020 to $4,916,463 in 2023, representing a 24% compound annual growth rate. Adjusted EBITDA margins have also increased along with the rapid sales growth, from 36.2% of sales in 2020 to 45.4% of sales in 2023.
These stats have been driven without medications such as GLP 1 (ie. semiglutide) but there is a significant opportunity if these additional options were added.
Current owner is retiring and relocating. Sale is confidential. Upon signing an NDA, current owner will provide all the financials.
